SeraCare Life Sciences Introduces IVD Labeled ACCURUN Controls for Women's Health

MILFORD, Mass., Nov. 12, 2013 /PRNewswire/ -- SeraCare Life Sciences, a manufacturer of life sciences tools, bulk plasma, and quality controls for diagnostic companies and clinical laboratories, announced availability of IVD labeled ACCURUN^® controls for Women's Health. These Human Papilloma Virus (HPV) and Chlamydia trachomatis/Neisseria gonorrhea (Ct/Ng) offerings are cellular-based independent controls used by clinical laboratories to challenge their in vitro diagnostic assays.

(Photo: http://photos.prnewswire.com/prnh/20131112/NE14697)

"Our investment in making these controls available as IVD labeled products is an indicator of SeraCare's focus on the Women's Health market," said Vince Smith, director of the Clinical Lab business unit at SeraCare. "Our ACCURUN products are well-regarded in the industry as whole process controls, providing a rigorous challenge to the entire testing procedure."

ACCURUN 372 HPV DNA positive controls challenge HPV tests from extraction through amplification and detection. They are cellular-based controls formulated for use with laboratory tests that detect HPV DNA in human cervical samples. ACCURUN 341 Ct/Ng controls closely mimic human samples due to whole organism structure and deliver convenient plug and play design for direct placement on the instrument.

About SeraCare Life Sciences
SeraCare, a portfolio company of Linden Capital Partners, works with diagnostics researchers, IVD manufacturers, and clinical laboratories to shape the future of medical diagnostics. Our innovative portfolio includes ACCURUN^® quality controls, AccuTrak™, AccuSpan™, AccuSet™ and AccuVert™ panels, KPL™ antibodies and immunoassay reagents, SeraCon™ processed plasma, specialty human blood products, and Complete BioCollections™ materials. SeraCare helps bridge the gap between today's diagnostic solutions and tomorrow's emerging technologies.

About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life science industries. Linden's strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, and services segments of healthcare.

Marsha Ann Marsh
SeraCare Life Sciences
+1 508.244.6400 ext. 6106
[email protected]

SOURCE SeraCare Life Sciences